RecruitingAlzheimer DementiaLate Onset Alzheimer DiseaseNeurodegenerative Diseases
Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease
Eligible age
55–80 yrs
Accepts
All genders
Locations
4 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
A phase 2, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of Allopregnanolone as a regenerative therapeutic for Alzheimer's disease.
Sponsor: University of Arizona
Where it's recruiting
Arizona
Scottsdale · Tucson
California
Costa Mesa · Los Alamitos · Santa Ana
Florida
Miami · Orlando · Winter Park
Massachusetts
Waltham
Source: ClinicalTrials.gov · NCT04838301 · last updated 2026-03-13